Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Obesity induces low-grade chronic inflammation, manifested by proinflammatory polarization of adipose tissue innate and adaptive resident and recruited immune cells that contribute to insulin resistance (IR). The glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that mediates postprandial insulin secretion and has anabolic effects on the adipose tissue. Importantly, recent evidence suggested that GIP is a potential suppressor of inflammation in several metabolic models. In this study, we aimed to investigate the immunoregulatory role of GIP in a murine model of diet-induced obesity (DIO) using the long-acting GIP analog [d-Ala2]GIP. Administration of [d-Ala2]GIP resulted in adipocytes of increased size, increased levels of adipose tissue lipid droplet proteins, indicating better lipid storage capacity, and reduced adipose tissue inflammation. Flow cytometry analysis revealed reduced numbers of inflammatory Ly6Chi monocytes and F4/80hiCD11c+ macrophages, associated with IR. In addition, [d-Ala2]GIP reduced adipose tissue infiltration of IFN-γ–producing CD8+ and CD4+ T cells. Furthermore, [d-Ala2]GIP treatment induced a favorable adipose tissue adipokine profile, manifested by a prominent reduction in key inflammatory cytokines (TNF-α, IL-1β, IFN-γ) and chemokines (CCL2, CCL8, and CCL5) and an increase in adiponectin. Notably, [d-Ala2]GIP also reduced the numbers of circulating neutrophils and proinflammatory Ly6Chi monocytes in mice fed regular chow or a high-fat diet. Finally, the beneficial immune-associated effects were accompanied by amelioration of IR and improved insulin signaling in liver and adipose tissue. Collectively, our results describe key beneficial immunoregulatory properties for GIP in DIO and reveal that its augmentation ameliorates adipose tissue inflammation and improves IR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and the action of tirzepatide on glucose-dependent insulinotropic polypeptide receptors may produce incremental anti-inflammatory effects.44,50”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [50]
Citations
Cites
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“Incretins, glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (GIP), are hormones secreted from the small bowel in response to nutrients, and they act by increasing insulin secretion from the pancreas (18, 19).”
BackgroundAdipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1937 · Cited by 3,188
Body-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230
Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A. B., Benoist, C., Shoelson, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2002 · Cited by 2,145 · cited 1×
“Notably, obesity is associated with a reduction in anti-inflammatory Foxp3 regulatory T cells (13), in parallel with an increase in the accumulation of proinflammatory CD8 T cells and Th1 CD4 T cells in adipose tissue (14, 15).”
BackgroundThe cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
Cited by
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Worthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“…GIP analogue [d-Ala(2)] GIP for 8 weeks have increased lipid storage, yet reduced expression of pro-inflammatory cytokines and chemokines and decreased macrophage accumulation in WAT, associated with reduced insulin resistance, compared with control HFD-fed mice not treated with a GIP analogue 67 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Jouy, S. H., Mohan, S., Scichilone, G., Mostafa, A., & Mahmoud, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092129 · Cited by 110
Verón, H. E., Gauffin-Cano, P., Fabersani, E., Sanz, Y., Isla, M. I., Fernández-Espinar, M. T., Gil, J. V., & Torres, S. (2019) · Food & Function · doi:10.1039/c8fo01591k · Cited by 88
Rizvi, A. A., & Rizzo, M. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s351982 · Cited by 65
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Fukuda, M. (2021) · Diabetes · doi:10.2337/dbi21-0001 · Cited by 69
S100 proteins in obesity: liaisons dangereuses
Riuzzi, F., Chiappalupi, S., Arcuri, C., Giambanco, I., Sorci, G., & Donato, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03257-4 · Cited by 78
Xia, Y., Jin, J., Sun, Y., Kong, X., Shen, Z., Yan, R., Huang, R., Liu, X., Xia, W., Ma, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113499 · Cited by 78
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
“44,50 The results of the present study should be considered in light of its strengths and limitations.”
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 68
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70
Self-citationGIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Pantea Stoian, A., Al-Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 54
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Energy restriction and potential energy restriction mimetics
Nikolai, S., Pallauf, K., Huebbe, P., & Rimbach, G. H. (2015) · Nutrition Research Reviews · doi:10.1017/s0954422415000062 · Cited by 50
Kim, D., Nepali, S., Son, J.-S., Poudel, B., Lee, J., & Lee, Y. (2015) · Pharmacognosy Magazine · doi:10.4103/0973-1296.160470 · Cited by 46
Gong, M., Wu, Z., Xu, S., Li, L., Wang, X., Guan, X., & Zhang, H. (2019) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-019-0888-9 · Cited by 45
Dai, M., Wu, L., Wang, P., Zheng, W., Xu, X., & Wang, D. W. (2017) · Scientific Reports · doi:10.1038/srep46743 · Cited by 43
Jujić, A., Nilsson, P. M., Atabaki-Pasdar, N., Dieden, A., Tuomi, T., Franks, P. W., Holst, J. J., Torekov, S. S., Ravassa, S., Díez, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1318 · Cited by 33
Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 36
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Independent risk factors for hypoxemia after surgery for acute aortic dissection
Sheng, W., Yang, H., Chi, Y.-F., Niu, Z., Lin, M., & Long, S. (2015) · Saudi Medical Journal · doi:10.15537/smj.2015.8.11583 · Cited by 34
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
Shah, F. A., Mahmud, H., Gallego‐Martin, T., Jurczak, M. J., O'Donnell, C. P., & McVerry, B. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00296 · Cited by 33
Regulation of nutrition-associated receptors in blood monocytes of normal weight and obese humans
Pivovarova‐Ramich, O., Hornemann, S., Weimer, S., Lu, Y., Murahovschi, V., Zhuk, S., Seltmann, A., Malashicheva, A., Kostareva, A. A., Kruse, M., et al. (2015) · Peptides · doi:10.1016/j.peptides.2014.11.009 · Cited by 30
Meng, F., Lin, Y., Yang, M. H., Li, M., Yang, G., Hao, P., & Li, L. (2018) · BioMed Research International · doi:10.1155/2018/4507659 · Cited by 30
Mantelmacher, F. D., Fishman, S., Cohen, K., Pasmanik Chor, M., Yamada, Y., Zvibel, I., & Varol, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601441 · Cited by 27
Self-citationA Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Gopan, G., Jose, J., Khot, K. B., & Bandiwadekar, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125374 · Cited by 26
Anti‐inflammatory role of glucose‐dependent insulinotropic polypeptide in periodontitis
Suzuki, Y., Nakamura, N., Miyabe, M., Nishikawa, T., Miyajima, S., Adachi, K., Mizutani, M., Kikuchi, T., Miyazawa, K., Goto, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12450 · Cited by 27
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24
Self-citationThe role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“However, in rodent studies overexpression of GIP and administration of long-acting GIP agonists have been reported to enhance insulin sensitivity (42,43).”
BackgroundGut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 23
Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Efimova, I., Steinberg, I., Zvibel, I., Neumann, A., Mantelmacher, F. D., Drucker, D. J., Fishman, S., & Varol, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643144 · Cited by 22
Self-citationPGBR extract ameliorates TNF‐α induced insulin resistance in hepatocytes
Chen, F., Shen, K., Chen, J., Lin, H., Hao, C., Yen, H., & Shaw, S. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.08.009 · Cited by 20
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., & Negm, W. A. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01239-4 · Cited by 20
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Distasi, M. R., Mund, J. A., Bohlen, H. G., Miller, S. J., Ingram, D. A., Dalsing, M. C., & Unthank, J. L. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00180.2015 · Cited by 17
Kimita, W., Bharmal, S. H., Ko, J., & Petrov, M. S. (2022) · Translational research · doi:10.1016/j.trsl.2022.07.001 · Cited by 15
Zhao, Y., Yue, Y., Wang, Y., Zhao, W., & Feng, G. (2021) · American Journal of Translational Research · Cited by 14
Han, F., Li, G., Dai, S., & Huang, J. (2015) · Molecular BioSystems · doi:10.1039/c5mb00480b · Cited by 14
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro
Quadros-Pereira, L., Nery-Neto, J. A. D. O., da Silva, E. M., Doretto-Silva, L., Yariwake, V. Y., Câmara, N. O. S., & Andrade‐Oliveira, V. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113730 · Cited by 11
Lin, A., Kitaura, H., Ohori, F., Noguchi, T., Marahleh, A., Ma, J., Ren, J., Miura, M., Fan, Z., Narita, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052555 · Cited by 10
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
Does the “obesity paradox” exist after transcatheter aortic valve implantation?
Luo, Z.-R., Chen, L., & Qiu, H. (2022) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-022-01910-x · Cited by 8
He, X. (2022) · European Journal of Inflammation · doi:10.1177/20587392211070402 · Cited by 7
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
The role of the incretin GIP in inflammation
Rossi, G., Bucciarelli, L. G., Cimino, V., & Fiorina, P. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02719-w · Cited by 7
Incretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
Self-citationThe GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Oe, Y., Omori, T., Aimono, E., Furukawa, S., Kitakawa, H., Tateno, M., Sakai, K., & Cho, K. Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1501984 · Cited by 5
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
Henriksen, K., Jørgensen, A., Kaur, S., Gerwig, R. H., Svane, C. A. B., Knop, F. K., & Størling, J. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112522 · Cited by 4
Sue, M., Watanabe, M., Inoue, A., Katayama, A., Teshigawara, S., Matsushita, Y., Takeda, M., Iseda, I., Eguchi, J., & Hida, K. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70173 · Cited by 4
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Bauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 4
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Kwiecień, S., Szlachcic, A., Wójcik-Grzybek, D., Śliwowski, Z., Strzałka, M., Szczyrk, U., Ptak‐Belowska, A., & Brzozowski, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062827 · Cited by 2
Xia, X., Lin, Q., Zhou, Z. M., & Chen, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109377 · Cited by 2
Potential missed opportunities to improve long-term liver allograft health
Fallahzadeh, M. A., McCaughan, G. W., & O’Leary, J. G. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000720 · Cited by 2
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
Patel, K. S., Fakhoury, B., Parmar, K., Jahagirdar, V., Sanyal, A. J., Arab, J. P., & Tariq, R. (2026) · Intestinal Research · doi:10.5217/ir.2026.00152 · Cited by 1
Shamsunder, M. G. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/g333-xg88
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6979-5
da Silva, D. R. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Vyavahare, S. S. (2018) · Ulster University Research Portal (Ulster University)
Anti-GIP antibodies and future diabetes related risk: an eight-year prospective cohort study
Hashimoto, T., Ohtake, N., Okamoto, T., Zhang, B., Yoshida, Y., Takizawa, H., Yamaga, M., Yoshida, T., Kajiyama, A., Yagihashi, T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1811527
GLP-1R/GIPR DUAL AGONISM REDUCES INTESTINAL LIPID SECRETION
Tabatabaeian, F. (2026) · HARVEST (University of Saskatchewan)
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Masashi, I. I. D. A., Warita, K., & Asano, A. (2026) · Journal of Veterinary Medical Science · doi:10.1292/jvms.26-0476
Metadata
- Authors
- Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S.
- Affiliations
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Varol, Chen
- Zvibel, Isabel
- Spektor, Lior
- Vugman, Milena
- Thurm, Tamar
- Elmaliah, Elinor
- Halpern, Zamir
- Fishman, Sigal
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10
- Volume
- 193
- Issue
- 8
- Pages
- 4002-4009
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1942626993
- Cited by
- 89
- References
- 39
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 19 · 2023: 5 · 2022: 9 · 2021: 9 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 1 · 2015: 8
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- glucose-dependent insulinotropic polypeptide, diet-induced obesity, adipose tissue inflammation, insulin resistance, immune regulation, adipose tissue macrophages, Ly6Chi monocytes, T cell infiltration, adipokines, adiponectin, chemokines, TNF-α, interferon-gamma, insulin signaling, high-fat diet, neutrophils
- MeSH terms
- Insulin Secretion, Adipose Tissue, Animals, Antigens, Differentiation, Antigens, Ly, Blood Glucose, Gastric Inhibitory Polypeptide, Humans, Insulin, Insulin Resistance, Interferon-gamma, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Neutrophils, Obesity, Receptors, Gastrointestinal Hormone, Tumor Necrosis Factor-alpha, Signal Transduction, CD4-Positive T-Lymphocytes, T-Lymphocyte Subsets, Adipocytes, CD8-Positive T-Lymphocytes, Chemokine CCL2, Chemokine CCL5, CD11c Antigen, Mice, Adiponectin, Interleukin-1beta, Chemokine CCL8, Diet, High-Fat, Lipid Droplets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.